Selected research
Industry Research
Custom Recombinant Antibody Conversion Service Industry Research Report 2026
Market perspective
The global Custom Recombinant Antibody Conversion Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Custom Recombinant Antibody Conversion Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Custom Recombinant Antibody Conversion Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Custom Recombinant Antibody Conversion Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Custom Recombinant Antibody Conversion Service include Creative Biolabs, Abnova Corporation, GenScript Biotech Corporation, Rockland Immunochemicals Inc., LakePharma Inc., ProteoGenix, ProMab Biotechnologies Inc., Sino Biological Inc. and BOC Sciences, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Custom Recombinant Antibody Conversion Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Custom Recombinant Antibody Conversion Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Custom Recombinant Antibody Conversion Service Market by Company
Creative Biolabs
Abnova Corporation
GenScript Biotech Corporation
Rockland Immunochemicals Inc.
LakePharma Inc.
ProteoGenix
ProMab Biotechnologies Inc.
Sino Biological Inc.
BOC Sciences
Absolute Antibody Ltd.
OriGene Technologies Inc.
Novus Biologicals LLC
BioLegend Inc.
RayBiotech Inc.
Proteintech Group Inc.
ACROBiosystems
Custom Recombinant Antibody Conversion Service Segment by Type
Fab and scFv Antibody Fragment Production
Chimeric Antibody Production
Bispecific Antibody Production
Antibody Labeling and Conjugation
Custom Recombinant Antibody Conversion Service Segment by Application
Research and Development
Diagnostics
Therapeutics
Biomanufacturing
Agriculture and Food
Others
Custom Recombinant Antibody Conversion Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Custom Recombinant Antibody Conversion Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Custom Recombinant Antibody Conversion Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Custom Recombinant Antibody Conversion Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Custom Recombinant Antibody Conversion Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fab and scFv Antibody Fragment Production
- Chimeric Antibody Production
- Bispecific Antibody Production
- Antibody Labeling and Conjugation
Applications
- Research and Development
- Diagnostics
- Therapeutics
- Biomanufacturing
- Agriculture and Food
- Others
Companies covered
- Creative Biolabs
- Abnova Corporation
- GenScript Biotech Corporation
- Rockland Immunochemicals Inc.
- LakePharma Inc.
- ProteoGenix
- ProMab Biotechnologies Inc.
- Sino Biological Inc.
- BOC Sciences
- Absolute Antibody Ltd.
- OriGene Technologies Inc.
- Novus Biologicals LLC
- BioLegend Inc.
- RayBiotech Inc.
- Proteintech Group Inc.
- ACROBiosystems
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Custom Recombinant Antibody Conversion Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Fab and scFv Antibody Fragment Production
- 2.2.3 Chimeric Antibody Production
- 2.2.4 Bispecific Antibody Production
- 2.2.5 Antibody Labeling and Conjugation
- 2.3 Custom Recombinant Antibody Conversion Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Research and Development
- 2.3.3 Diagnostics
- 2.3.4 Therapeutics
- 2.3.5 Biomanufacturing
- 2.3.6 Agriculture and Food
- 2.3.7 Others
- 2.4 Assumptions and Limitations
3 Custom Recombinant Antibody Conversion Service Breakdown Data by Type
- 3.1 Global Custom Recombinant Antibody Conversion Service Historic Market Size by Type (2021-2026)
- 3.2 Global Custom Recombinant Antibody Conversion Service Forecasted Market Size by Type (2027-2032)
4 Custom Recombinant Antibody Conversion Service Breakdown Data by Application
- 4.1 Global Custom Recombinant Antibody Conversion Service Historic Market Size by Application (2021-2026)
- 4.2 Global Custom Recombinant Antibody Conversion Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Custom Recombinant Antibody Conversion Service Market Perspective (2021-2032)
- 5.2 Global Custom Recombinant Antibody Conversion Service Growth Trends by Region
- 5.2.1 Global Custom Recombinant Antibody Conversion Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Custom Recombinant Antibody Conversion Service Historic Market Size by Region (2021-2026)
- 5.2.3 Custom Recombinant Antibody Conversion Service Forecasted Market Size by Region (2027-2032)
- 5.3 Custom Recombinant Antibody Conversion Service Market Dynamics
- 5.3.1 Custom Recombinant Antibody Conversion Service Industry Trends
- 5.3.2 Custom Recombinant Antibody Conversion Service Market Drivers
- 5.3.3 Custom Recombinant Antibody Conversion Service Market Challenges
- 5.3.4 Custom Recombinant Antibody Conversion Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Custom Recombinant Antibody Conversion Service Players by Revenue
- 6.1.1 Global Top Custom Recombinant Antibody Conversion Service Players by Revenue (2021-2026)
- 6.1.2 Global Custom Recombinant Antibody Conversion Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Custom Recombinant Antibody Conversion Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Custom Recombinant Antibody Conversion Service Head Office and Area Served
- 6.4 Global Custom Recombinant Antibody Conversion Service Players, Product Type & Application
- 6.5 Global Custom Recombinant Antibody Conversion Service Manufacturers Established Date
- 6.6 Global Custom Recombinant Antibody Conversion Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Custom Recombinant Antibody Conversion Service Market Size (2021-2032)
- 7.2 North America Custom Recombinant Antibody Conversion Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Custom Recombinant Antibody Conversion Service Market Size by Country (2021-2026)
- 7.4 North America Custom Recombinant Antibody Conversion Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Custom Recombinant Antibody Conversion Service Market Size (2021-2032)
- 8.2 Europe Custom Recombinant Antibody Conversion Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Custom Recombinant Antibody Conversion Service Market Size by Country (2021-2026)
- 8.4 Europe Custom Recombinant Antibody Conversion Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Custom Recombinant Antibody Conversion Service Market Size (2021-2032)
- 9.2 Asia-Pacific Custom Recombinant Antibody Conversion Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Custom Recombinant Antibody Conversion Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Custom Recombinant Antibody Conversion Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Custom Recombinant Antibody Conversion Service Market Size (2021-2032)
- 10.2 South America Custom Recombinant Antibody Conversion Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Custom Recombinant Antibody Conversion Service Market Size by Country (2021-2026)
- 10.4 South America Custom Recombinant Antibody Conversion Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Custom Recombinant Antibody Conversion Service Market Size (2021-2032)
- 11.2 Middle East & Africa Custom Recombinant Antibody Conversion Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Custom Recombinant Antibody Conversion Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Custom Recombinant Antibody Conversion Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Creative Biolabs
- 12.1.1 Creative Biolabs Company Information
- 12.1.2 Creative Biolabs Business Overview
- 12.1.3 Creative Biolabs Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.1.4 Creative Biolabs Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.1.5 Creative Biolabs Recent Developments
- 12.2 Abnova Corporation
- 12.2.1 Abnova Corporation Company Information
- 12.2.2 Abnova Corporation Business Overview
- 12.2.3 Abnova Corporation Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.2.4 Abnova Corporation Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.2.5 Abnova Corporation Recent Developments
- 12.3 GenScript Biotech Corporation
- 12.3.1 GenScript Biotech Corporation Company Information
- 12.3.2 GenScript Biotech Corporation Business Overview
- 12.3.3 GenScript Biotech Corporation Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.3.4 GenScript Biotech Corporation Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.3.5 GenScript Biotech Corporation Recent Developments
- 12.4 Rockland Immunochemicals Inc.
- 12.4.1 Rockland Immunochemicals Inc. Company Information
- 12.4.2 Rockland Immunochemicals Inc. Business Overview
- 12.4.3 Rockland Immunochemicals Inc. Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.4.4 Rockland Immunochemicals Inc. Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.4.5 Rockland Immunochemicals Inc. Recent Developments
- 12.5 LakePharma Inc.
- 12.5.1 LakePharma Inc. Company Information
- 12.5.2 LakePharma Inc. Business Overview
- 12.5.3 LakePharma Inc. Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.5.4 LakePharma Inc. Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.5.5 LakePharma Inc. Recent Developments
- 12.6 ProteoGenix
- 12.6.1 ProteoGenix Company Information
- 12.6.2 ProteoGenix Business Overview
- 12.6.3 ProteoGenix Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.6.4 ProteoGenix Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.6.5 ProteoGenix Recent Developments
- 12.7 ProMab Biotechnologies Inc.
- 12.7.1 ProMab Biotechnologies Inc. Company Information
- 12.7.2 ProMab Biotechnologies Inc. Business Overview
- 12.7.3 ProMab Biotechnologies Inc. Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.7.4 ProMab Biotechnologies Inc. Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.7.5 ProMab Biotechnologies Inc. Recent Developments
- 12.8 Sino Biological Inc.
- 12.8.1 Sino Biological Inc. Company Information
- 12.8.2 Sino Biological Inc. Business Overview
- 12.8.3 Sino Biological Inc. Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.8.4 Sino Biological Inc. Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.8.5 Sino Biological Inc. Recent Developments
- 12.9 BOC Sciences
- 12.9.1 BOC Sciences Company Information
- 12.9.2 BOC Sciences Business Overview
- 12.9.3 BOC Sciences Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.9.4 BOC Sciences Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.9.5 BOC Sciences Recent Developments
- 12.10 Absolute Antibody Ltd.
- 12.10.1 Absolute Antibody Ltd. Company Information
- 12.10.2 Absolute Antibody Ltd. Business Overview
- 12.10.3 Absolute Antibody Ltd. Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.10.4 Absolute Antibody Ltd. Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.10.5 Absolute Antibody Ltd. Recent Developments
- 12.11 OriGene Technologies Inc.
- 12.11.1 OriGene Technologies Inc. Company Information
- 12.11.2 OriGene Technologies Inc. Business Overview
- 12.11.3 OriGene Technologies Inc. Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.11.4 OriGene Technologies Inc. Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.11.5 OriGene Technologies Inc. Recent Developments
- 12.12 Novus Biologicals LLC
- 12.12.1 Novus Biologicals LLC Company Information
- 12.12.2 Novus Biologicals LLC Business Overview
- 12.12.3 Novus Biologicals LLC Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.12.4 Novus Biologicals LLC Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.12.5 Novus Biologicals LLC Recent Developments
- 12.13 BioLegend Inc.
- 12.13.1 BioLegend Inc. Company Information
- 12.13.2 BioLegend Inc. Business Overview
- 12.13.3 BioLegend Inc. Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.13.4 BioLegend Inc. Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.13.5 BioLegend Inc. Recent Developments
- 12.14 RayBiotech Inc.
- 12.14.1 RayBiotech Inc. Company Information
- 12.14.2 RayBiotech Inc. Business Overview
- 12.14.3 RayBiotech Inc. Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.14.4 RayBiotech Inc. Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.14.5 RayBiotech Inc. Recent Developments
- 12.15 Proteintech Group Inc.
- 12.15.1 Proteintech Group Inc. Company Information
- 12.15.2 Proteintech Group Inc. Business Overview
- 12.15.3 Proteintech Group Inc. Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.15.4 Proteintech Group Inc. Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.15.5 Proteintech Group Inc. Recent Developments
- 12.16 ACROBiosystems
- 12.16.1 ACROBiosystems Company Information
- 12.16.2 ACROBiosystems Business Overview
- 12.16.3 ACROBiosystems Revenue in Custom Recombinant Antibody Conversion Service Business (2021-2026)
- 12.16.4 ACROBiosystems Custom Recombinant Antibody Conversion Service Product Portfolio
- 12.16.5 ACROBiosystems Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst